Balyasny Asset Management
TNGX icon

Balyasny Asset Management’s Tango Therapeutics TNGX Stock Holding History

Balyasny Asset Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$80.1M Sell
3,826,659
-1,451,921
-28% -$20.2M 0.1% 213
2025
Q4 		$46.8M Buy
5,278,580
+1,806,373
+52% +$15.6M 0.06% 376
2025
Q3 		$29.2M Buy
3,472,207
+224,744
+7% +$1.52M 0.04% 557
2025
Q2 		$16.6M Buy
3,247,463
+27,892
+0.9% +$69K 0.03% 736
2025
Q1 		$4.41M Sell
3,219,571
-59,625
-2% -$146K 0.01% 1306
2024
Q4 		$10.1M Buy
3,279,196
+592,000
+22% +$2.75M 0.02% 956
2024
Q3 		$20.7M Buy
2,687,196
+2,410,187
+870% +$23M 0.03% 612
2024
Q2 		$2.38M Buy
+277,009
New +$2.14M ﹤0.01% 1468
2023
Q4 		– Sell
-844,377
Closed -$9.51M – 2906
2023
Q3 		$9.51M Buy
+844,377
New +$5.15M 0.02% 862
2022
Q2 		– Sell
-31,781
Closed -$241K – 3185
2022
Q1 		$241K Buy
+31,781
New +$275K ﹤0.01% 1981

Other funds holding TNGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Balyasny Asset Management's TNGX Position: Q1 2026 in Review

Balyasny Asset Management reduced its Tango Therapeutics (TNGX) stake by 28% in Q1 2026, selling an estimated $20.2M and leaving 3,826,659 shares worth $80.1M. The position accounts for 0.1% of the portfolio, ranked #213.

Balyasny Asset Management first reported a position in TNGX in Q1 2022 and has held it in 10 quarters since. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • Balyasny Asset Management held 3,826,659 shares of Tango Therapeutics worth $80.1M as of Q1 2026.
  • Balyasny Asset Management sold 1,451,921 Tango Therapeutics shares in Q1 2026, an estimated $20.2M.
  • Tango Therapeutics made up 0.1% of Balyasny Asset Management's portfolio in Q1 2026, its #213 holding.
  • Balyasny Asset Management first reported a position in Tango Therapeutics in Q1 2022 and has held it in 10 quarters since.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.